Doctors can now administer the an anti-inflammatory to all UK hospitalised COVID-19 patients requiring oxygen, including those on ventilators.
The move follows data from the UK RECOVERY trial showing that the drug cut the risk death in COVID-19 patients on ventilation by as much as 35% and patients on oxygen by 20%, reducing the total 28-day mortality rate by 17%.
Funded by the UK government, via the National Institute for Health Research (NIHR) and UK Research and Innovation (UKRI), the Oxford University UK RECOVERY trial is the first clinical trial anywhere in the world to show a treatment provides significant impact in reducing patient mortality.
“The positive findings on dexamethasone follow the disappointing findings on hydroxychloroquine. Together these two results illustrate the power of properly conducted clinical trials and the inherent danger of assuming things work without robust data,” noted deputy chief medical officer, Professor Jonathan Van-Tam…